Hennion & Walsh Asset Management, Inc. Aldeyra Therapeutics, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $1.89 Billion
- Q2 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 88,122 shares of ALDX stock, worth $470,571. This represents 0.02% of its overall portfolio holdings.
Number of Shares
88,122
Previous 81,178
8.55%
Holding current value
$470,571
Previous $265,000
9.81%
% of portfolio
0.02%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding ALDX
# of Institutions
106Shares Held
35.1MCall Options Held
153KPut Options Held
83.9K-
Perceptive Advisors LLC New York, NY9.28MShares$49.5 Million0.89% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$29.2 Million12.24% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$20 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$19.3 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.6MShares$8.54 Million0.12% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $311M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...